HLA-DPB1 Antibody

Code CSB-PA14809A0Rb
Size US$166
Order now
Image
  • Western blot
    All lanes: HLA-DPB1 antibody at 2µg/ml
    Lane 1: sw1990 whole cell lysate
    Lane 2: HGC27 whole cell lysate
    Secondary
    Goat polyclonal to rabbit IgG at 1/10000 dilution
    Predicted band size: 30 kDa
    Observed band size: 30 kDa

  • Immunohistochemistry of paraffin-embedded human tonsil tissue using CSB-PA14809A0Rb at dilution of 1:50

The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) HLA-DPB1 Polyclonal antibody
Uniprot No.
Target Names
HLA-DPB1
Alternative Names
beta1 domain MHC class II HLA DPB antibody; class II histocompatibility antigen; DP(W4) beta chain antibody; class II HLA beta chain antibody; DP beta 1 chain antibody; DP(W4) beta chain antibody; DPB1 antibody; DPB1_HUMAN antibody; HLA class II histocompatibility antigen antibody; HLA class II histocompatibility antigen; DP beta 1 chain antibody; HLA class II histocompatibility antigen; DP(W4) beta chain antibody; HLA DP14-beta chain antibody; HLA-DP antibody; HLA-DP histocompatibility type; beta-1 subunit antibody; HLA-DP1B antibody; HLA-DPB antibody; HLA-DPB1 antibody; major histocompatibility complex class II antigen beta chain antibody; major histocompatibility complex; class II; DP beta 1 antibody; MHC class II antigen beta chain antibody; MHC class II antigen DP beta 1 chain antibody; MHC class II antigen DPB1 antibody; MHC class II antigen DPbeta1 antibody; MHC class II HLA-DP-beta-1 antibody; MHC class II HLA-DRB1 antibody; MHC HLA DPB1 antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human HLA class II histocompatibility antigen, DP beta 1 chain protein (30-225AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated

The HLA-DPB1 Antibody (Product code: CSB-PA14809A0Rb) is Non-conjugated. For HLA-DPB1 Antibody with conjugates, please check the following table.

Available Conjugates
Conjugate Product Code Product Name Application
HRP CSB-PA14809B0Rb HLA-DPB1 Antibody, HRP conjugated ELISA
FITC CSB-PA14809C0Rb HLA-DPB1 Antibody, FITC conjugated
Biotin CSB-PA14809D0Rb HLA-DPB1 Antibody, Biotin conjugated ELISA
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form
Liquid
Tested Applications
ELISA, WB, IHC
Recommended Dilution
Application Recommended Dilution
WB 1:1000-1:5000
IHC 1:20-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
Gene References into Functions
  1. Data suggest that HLA-DP molecules with beta-chains encoding Gly84 (DP(84Gly)) uses both class I and II antigen-processing pathways to present peptides derived from intracellular and extracellular sources. PMID: 28489076
  2. HLA-DP polymorphisms (rs3077 and rs9277535) were associated with Systemic lupus erythematosus susceptibility in a Chinese population PMID: 28094303
  3. High frequency expression of DPB1*0401 and *0601 are significantly associated with susceptibility to rheumatoid arthritis, it may be a risk factor for occurrence of rheumatoid arthritis. Low frequency expression of DPB1*0101, *0402 and *0501 may be negatively associated with rheumatoid arthritis, it may be a protective factor for occurrence of rheumatoid arthritis. PMID: 29425827
  4. The rs3117242 of HLA-DPB1 could be considered a genetic risk factor for granulomatosis with polyangiitis in Chinese Han people. PMID: 26014903
  5. HLA-DPB1*05:01 gene was associated with the geographical region of PV and the BTNL2 gene was significantly associated with family history and age of onset of PV. In conclusion, the HLA-DPB1*05:01 and BTNL2 genes might be responsible for the complicacy of clinical features. PMID: 28581127
  6. In this single-center study, HLA-DPB1 matching influenced outcomes of patients undergoing ASCT for hematologic malignancy. PMID: 28632323
  7. HLA-DPB1*15:01 allele was more frequent in the spontaneous seroconverted control group compared to Chronic hepatitis B Turkish patients. PMID: 29560661
  8. Genotyping and expression analysis in HLA class II gene revealed that two single nucleotide polymorphisms of HLA-DPB1 (rs2071025 and rs3116996) were significantly correlated to RNA expression and progression of hepatitis C virus-related liver diseases. PMID: 28332201
  9. Amino acid changes in the allergen-binding pocket of HLA-DPbeta1 are likely to influence pollinosis/sensitization to the allergenic peptide of JC pollen and determine the pollinosis risk for each individual exposed to JC pollen. PMID: 28460831
  10. The results showed that rs9277535 HLA-DPB1 allele frequency is associated with chronic hepatitis B infection in the Turkish patients. PMID: 28119119
  11. report contributes to emerging data showing clinical significance of the HLA-DP region genetic markers beyond structural matching of DPB1 alleles. PMID: 27595289
  12. The HLA-DP rs9277535 variant genotypes were directly associated with hepatitis B virus persistence compared to healthy controls. PMID: 27291710
  13. No statistically significant association was found between rs9277535 SNP and chronic hepatitis B. PMID: 28613373
  14. Two new signals were observed at genome-wide significance (P < 5 x 10-8), namely, rs7216064 (17q24.3, BPTF), for overall lung adenocarcinoma risk, and rs3817963 (6p21.3, BTNL2) which is specific to cases with EGFR mutations. In further sub-analyses by EGFR status, rs9387478 (ROS1/DCBLD1) and rs2179920 (HLA-DPB1) showed stronger estimated associations in EGFR-positive compared to EGFR-negative cases PMID: 28025329
  15. we show strong immunogenicity of HLA-DPB1 mismatch alleles in CD45RA-selected CD4 T cells of stem-cell donors and introduce a novel strategy to reliably generate HLA-DPB1-specific CD4 CTL that might be powerful cellular therapeutics in relapsed or refractory AML after HSCT. PMID: 27479183
  16. There was no increased risk of rheumatoid arthritis in mothers of children with phenylalanine at position 9 of DPB1. PMID: 28391248
  17. rs141530233 and rs1042169 at the HLA-DPB1 locus are associated with ANCA-associated vasculitis risk. PMID: 28029757
  18. Seven nonconservative AA substitutions in peptide-binding positions had a significantly stronger impact on DeltaFD compared with 5 others (P = .0025), demonstrating qualitative differences in the relative impact of AA polymorphism in HLA-DPB1. PMID: 27162243
  19. Study showed that HLA-DQ (rs7453920) was associated with prognosis of liver transplant recipients. The A allele of rs7453920 served as a protective factor in liver function recovery. HLA-DP (rs3077 and rs9277535) did not show any correlation with the hepatitis B virus infection and prognosis. PMID: 28640108
  20. two dermatomyositis susceptibility loci at 7q34 and 10q24.2 PMID: 27153935
  21. this study shows that HLA-DP gene polymorphisms are associated with ankylosing spondylitis in Southwest China PMID: 27394003
  22. DRB1*13:02 (P = 0.0011, Pc = 0.0319, odds ratio [OR] 0.46, 95% confidence interval [CI] 0.29-0.73), DRB1*14:06 (P = 6.60X10-5, Pc = 0.0020, OR 0.05, 95%CI 0.01-0.41), DQB1*03:01 (P = 0.0009, Pc = 0.0150, OR 0.56, 95%CI 0.40-0.79), and DPB1*02:01 (P = 5.16X10-6, Pc = 8.77X10-5, OR 0.52, 95%CI 0.39-0.69) were protectively associated with Systemic Sclerosis in Japanese. PMID: 27116456
  23. The HLA-DPB1*04:01:01G allele was significantly more frequent among women diagnosed with severe preeclampsia/eclampsia compared with controls. PMID: 27121092
  24. the HLA-DP/DQ clusters contribute independently to HBV infection, and the 3'-UTR region of HLA-DPB1 represents an important functional region involved in HBV infection PMID: 26197724
  25. Significant associations between chronic hepatitis B infection and five DPB1 alleles (two susceptibility alleles, DPB1(*) 05:01 and (*) 09:01, and three protective alleles, DPB1(*) 02:01, (*) 04:01, and (*) 04:02) were confirmed in Japanese individuals. PMID: 26449183
  26. The observed positive association between integrated HIV-1 DNA load and frequency of CD8(+)DR/DP/DQ(+) cells indicates that a close correlation between HIV persistence and immune activation continues during consistently suppressive therapy. PMID: 26498496
  27. Our results further confirm that genetic variants in the HLA-DP locus are strongly associated with reduced HBV infection and increased the likelihood of spontaneous viral clearance. PMID: 26462556
  28. Thyroid autoimmunity is highly prevalent in type 1 diabetes mellitus patients and the risk is modulated by HLA-DRB1 and HLA-DPB1 loci. PMID: 26405068
  29. DQB1*06 and DPB1*13 have roles in modulating vaccine-induced antibody responses to affect HIV-1 acquisition PMID: 26180102
  30. rs9277535 in HLA-DPB1 is a significantly associated SNP associated with chronic hepatitis B virus infection and viral clearance. PMID: 24846544
  31. Cellular misfolded proteins rescued from degradation by MHC class II molecules seem to be involved in autoimmune diseases as a target for autoantibodies. (review) PMID: 26915265
  32. findings indicate the HLA-DPB1*13:01 and +550 A alleles are significantly associated with cervical squamous cell carcinoma (CSCC) risk in Taiwanese women; in addition, significant increase in CSCC risk was observed for HLA-DPB1*13:01-G and DPB1*02:01-A haplotypes PMID: 26031576
  33. There was a significant linkage disequilibrium between these HLA-DP candidate SNPs and HLA-DPB1 protective alleles PMID: 25389088
  34. This implies the potential of rs3128965 of HLA-DPB1 as a genetic marker for diagnosis and prediction of the AERD phenotype. PMID: 25536158
  35. HLA-DPB1*04:01 may reduce the risk of tissue transglutaminase autoantibodies, an early marker of celiac disease, among DR3-DQ2 children, confirming that additional variants in the HLA region influence the risk for celiac disease autoimmunity. PMID: 26010309
  36. Among recipients of HLA-DPB1-mismatched transplants from donors with the low-expression allele, recipients with the high-expression allele had a high risk of GVHD. PMID: 26267621
  37. Results identified new susceptibility variants to narcolepsy in HLA-DPB1 and HLA-DQB1 loci in Japanese patients. PMID: 25256355
  38. The affinities of peptides for Beryllium loaded HLA-DP2 were found to depend of their amino acid composition and the peptides carrying acidic group at positions 4 and 7 are among the strongest binders. PMID: 25369028
  39. Polymorphisms in HLA-DPB1 are strongly associated with interindividual differences in neutralizing antibody levels to rubella vaccination. PMID: 25293367
  40. This is the first report of the association between early Crohn's disease and the HLA DRB1*501 single nucleotide polymorphisms. PMID: 25664710
  41. No increase in sarcoidosis was seen with either Glu69 or beryllium exposure. In Glu69 positive men with exposure >/=10 years, the trend towards increasing rate of COPD was reversed; a significant interaction of duration of exposure and Glu69 was detected. PMID: 25305207
  42. Data indicate that thirty eight HLA-DPB1 alleles were found in the systemic scleroderma cohort. PMID: 24498086
  43. HLA-DPB1 alleles influence the kinetics of anti-hepatitis B antibodies in hepatitis B booster recipients. PMID: 24285177
  44. Data indicate that HLA-DP2 transgenic mice developed a beryllium-specific adaptive immune response composed of CD4+ T cells. PMID: 24912188
  45. Data indicate five members of of DPbeta chains containing Lys-69 and GGPM 84-87, which assemble with DRalpha. PMID: 24214983
  46. Our results demonstrated that the rs3077 and rs9277535 HLA-DP polymorphisms reduced hepatitis B virus infection and increased the likelihood of spontaneous viral clearance in some Asian populations. PMID: 23601003
  47. Studied three HLA-DP and IL28B SNPs of CHB patients with and without spontaneous HBsAg seroclearance. Haplotype analysis of HLA-DP polymorphisms showed association with HBsAg seroclearance. PMID: 23449268
  48. HLA-DRB1*04:01 and HLA-DPB1*04:01 alleles were detected at higher frequencies in influenza-seroprotected compared with non-seroprotected individuals. PMID: 23951151
  49. The conditional logistic regression tests showed that DPB1*04:01 is independently associated with non-obstructive azoospermia(NOA), confirming the involvement of the HLA region in the etiology of NOA in Japanese patients. PMID: 23934009
  50. We identified the SEMA6A and HLA-DP loci as significant contributors to risk for granulomatosis with polyangiitis, with the HLA-DPB1*04 allele almost completely accounting for the MHC association PMID: 23740775

Show More

Hide All

Subcellular Location
Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation.
Protein Families
MHC class II family
Database Links

HGNC: 4940

OMIM: 142858

KEGG: hsa:3115

STRING: 9606.ENSP00000408146

UniGene: Hs.485130

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*